Skip to main content
Fig. 1 | BMC Musculoskeletal Disorders

Fig. 1

From: Factors predicting pain and early discontinuation of tumour necrosis factor-α-inhibitors in people with rheumatoid arthritis: results from the British society for rheumatology biologics register

Fig. 1

Pain up to 1 year of follow up. a, c, e, g show mean (sd) of norm-based SF36-Bodily Pain Scores using all data available at each time point. The UK population has an average norm-based score of 50 (grey, solid line), and lower scores indicate worse pain. b, d, f,) show the individual patient data from the TNF-inhibitor cohort demonstrating the proportion of participants with pain levels stratified by the norm-based standard deviation of 10. a shows mean (sd) of SF36-Bodily Pain scores from baseline to year 1. c, e and g show mean (sd) of norm based SF36-Bodily Pain scores at 1 year stratified by treatment response using c EULAR criteria; e DAS28 remission; and g normal swollen joint count (SJC = 0) with normal ESR range. Panels b, d, f and h show the stratification of individual patient data by SF36-Bodily Pain score in the TNF-inhibitor cohort at 1 year follow up. The cross-hatched, light shaded portion represents “better than UK average SF36-Bodily Pain” (≥50) and darker shaded plain portions represent increasingly worse pain at 1 year (increments of 10, which is ~1 sd for norm based SF36 scores). b Proportions individual patients with increasing severity of SF36-Bodily Pain scores at 1 year follow up; d stratified by EULAR response criteria, f stratified by DAS28 remission criteria, and h stratified into normal ESR and SJC ranges

Back to article page